Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02973425 · ClinicalTrials.gov registry record · NA
Take a Break (TAB): mHealth-assisted Skills Building Challenge for Unmotivated Smokers
A NA study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- NA
- Development phase
- 433
- Enrollment target
NCT02973425: Completed NA study, sponsored by University of Massachusetts, Worcester.
NCT02973425 is a NA study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 433 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02973425, a NA study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- NA
- Development phase
- 433 participants
- Enrollment target
Study Summary
Take a Break (TAB) is a randomized trial designed to evaluate Nicotine Replacement Therapy (NRT)-sampling and a mHealth suite of apps. TAB is a time-limited self-efficacy and skills building experience for Motivation Phase smokers. TAB is designed to create a timeline within which motivation smokers will be encouraged to try a brief period of abstinence. Smokers in this Motivation Phase are relatively untapped in research available information. This project offers these smokers point-of-need technology support in the many components of the intervention..
Primary Outcome
Time to first quit attempt is measured by participant self-report of number of days from baseline to first quit attempt within a 6 month period. At the 6-month follow-up visit, the dates of all quit attempts were assessed using the Timeline Follow-Back Method and used to calculate time to first quit attempt.
Interventions
- BEHAVIORAL Take a Break as an augmentation to NRT-sampling in Motivation Phase
- BEHAVIORAL NRT and mHealth assessment tool without feedback
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 433 participants |
| Start Date | 2016-11-07 |
| Est. Completion | 2020-07-31 |
| Phase | NA |
What the finished NCT02973425 record still lists
NCT02973425 is an interventional study that assigns participants to a tested intervention. The registered 433 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 2 interventions - of which Take a Break as an augmentation to NRT-sampling in Motivation Phase is the first listed.
NCT02973425 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02973425 about?
NCT02973425 is a clinical study titled "Take a Break (TAB): mHealth-assisted Skills Building Challenge for Unmotivated Smokers". Take a Break (TAB) is a randomized trial designed to evaluate Nicotine Replacement Therapy (NRT)-sampling and a mHealth suite of apps. TAB is a time-limited self-efficacy and skills building experience for Motivation Phase smokers. TAB is designed to create a timeline within which motivation smokers...
What is the current status of trial NCT02973425?
This trial is currently completed. It is a NA study. The enrollment target is 433 participants. The study started on 2016-11-07. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT02973425?
The interventions under investigation include: Take a Break as an augmentation to NRT-sampling in Motivation Phase (BEHAVIORAL), NRT and mHealth assessment tool without feedback (BEHAVIORAL).
Who is sponsoring clinical trial NCT02973425?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02973425's enrollment target sits among peer trials
433 235th of 2000 higher than 1,766 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04743245 · 434 participants · NA
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
- NCT06471920 · 434 participants · NA
Improving Health for Patients With Chronic LBP in Rural Communities Through Telerehabilitation
- NCT07094113 · 434 participants · Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- NCT05271240 · 432 participants · Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI